Dr. Eric Van Cutsem on Regorafenib for Metastatic Colorectal Cancer
Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
There were minimal toxicities in the study, and all were consistent with what was found in the CORRECT study, which also investigated regorafenib in mCRC, said Van Cutsem. There were no new safety concerns found, although 40-50% of patients did require some dose modification. Common toxicities included hypertension, fatigue, and hand-foot-skin reaction.
Progression-free survival was also similar to the CORRECT study, which validated regorafenib's efficacy in a larger population, said Van Cutsem.
<<<
